Simris Alg AB (publ) (SIMRIS-B) - Total Liabilities
Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) has total liabilities worth Skr136.97 Million SEK (≈ $14.74 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital to net assets of Simris Alg AB (publ) to evaluate short-term liquidity relative to the company's equity base.
Simris Alg AB (publ) - Total Liabilities Trend (2012–2025)
This chart illustrates how Simris Alg AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Simris Alg AB (publ).
Simris Alg AB (publ) Competitors by Total Liabilities
The table below lists competitors of Simris Alg AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SUNL.TECH.G.ADR/2DL-00005
F:S790
|
Germany | €1.10 Billion |
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
Korea | ₩25.13 Billion |
|
Pergamon Status Dis Ticaret AS
IS:PSDTC
|
Turkey | TL4.93 Billion |
|
Scage Future American Depositary Shares
NASDAQ:SCAG
|
USA | $27.43 Million |
|
BOA Resources Ltd
AU:BOA
|
Australia | AU$133.40K |
|
Samjin LND Co. Ltd
KQ:054090
|
Korea | ₩94.84 Billion |
|
Cairn Homes PLC
LSE:CRN
|
UK | GBX522.49 Million |
|
J and Friends Holdings Limited
NASDAQ:JF
|
USA | $22.85 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Simris Alg AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Simris Alg AB (publ) net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 178.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Simris Alg AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Simris Alg AB (publ) (2012–2025)
The table below shows the annual total liabilities of Simris Alg AB (publ) from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr148.85 Million ≈ $16.02 Million |
-1.69% |
| 2024-12-31 | Skr151.42 Million ≈ $16.29 Million |
+1.66% |
| 2023-12-31 | Skr148.94 Million ≈ $16.03 Million |
-8.45% |
| 2022-12-31 | Skr162.68 Million ≈ $17.51 Million |
+1381.58% |
| 2021-12-31 | Skr10.98 Million ≈ $1.18 Million |
+13.88% |
| 2020-12-31 | Skr9.64 Million ≈ $1.04 Million |
-43.98% |
| 2019-12-31 | Skr17.21 Million ≈ $1.85 Million |
+71.18% |
| 2018-12-31 | Skr10.05 Million ≈ $1.08 Million |
-14.11% |
| 2017-12-31 | Skr11.71 Million ≈ $1.26 Million |
+6.13% |
| 2016-12-31 | Skr11.03 Million ≈ $1.19 Million |
-34.90% |
| 2015-12-31 | Skr16.94 Million ≈ $1.82 Million |
+1461.47% |
| 2014-12-31 | Skr1.08 Million ≈ $116.76K |
+54.44% |
| 2013-12-31 | Skr702.52K ≈ $75.60K |
+10.93% |
| 2012-12-31 | Skr633.30K ≈ $68.15K |
-- |
About Simris Alg AB (publ)
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more